#China #Shanghai #Frost & Sullivan #Drug Discovery #Viva Biotech

Viva Biotech's Award for Innovation in Drug Discovery

Viva Biotech, based in Shanghai, has recently been awarded the prestigious 2025 APAC Technology Innovation Leadership recognition by Frost & Sullivan. This accolade is particularly significant, as it emphasizes the company's transformative achievements within the integrated intelligent drug discovery industry. By utilizing artificial intelligence (AI) in its drug development platform, Viva Biotech is setting new standards, significantly accelerating timelines while reducing overall costs for its clients in the pharmaceutical research and development sphere.

Frost & Sullivan's recognition is reserved for companies that show exceptional strategy development and implementation, celebrating those that are reshaping industries through innovative approaches and excellent growth. Viva Biotech’s leadership in merging AI technologies with laboratory validations was a decisive factor in winning this award, as it allows the company to redefine the future of drug discovery and enhance partnerships with clients alongside a competitive innovation framework.

Key Innovations in Drug Discovery

Viva Biotech's cutting-edge AI-Driven Drug Discovery (AIDD) platform, comprising several key modules—V-Scepter, V-Orb, and V-Mantle—addresses long-standing challenges faced in drug design. The integration of predictive modeling, physics-based simulations, and generative AI ensures rapid validation and iterative refinement of drug candidates, fostering a more efficient discovery process.

V-Scepter, V-Orb, and V-Mantle Modules

1. V-Scepter: This module provides the backbone for automated parameterization of biological systems. It encompasses small molecules and peptides, including noncanonical amino acids, crucial for physics-based simulations and data-driven generative model applications.

2. V-Orb: Focusing on physics-driven modeling, this module optimizes the proprietary Free Energy Perturbation (FEP) calculation suites for various binder types, significantly enhancing the virtual screening process through active learning integrations.

3. V-Mantle: Hosting generative AI capabilities, V-Mantle primarily facilitates protein structure prediction, small molecule de novo design, epitope prediction, and antibody engineering workflows.

The combination of these modules allows for a seamless workflow that supports over 150 projects with more than 50 global clients. This platform is known to facilitate a 30-50% faster discovery process and achieve cost reductions of around 70%, thus enabling high success rates across a multitude of difficult targets.

The Future of Drug Discovery

Viva Biotech's commitment to innovation and adaptability within the pharmacological research landscape is clearly demonstrated through its ongoing investments in AI technologies and structure-based discovery models. These efforts pave the way for quicker decision-making and support first-in-class programs for a worldwide clientele.

Dr. Derek Ren, CEO of Viva Biotech, expressed gratitude for the recognition: "Receiving this award from Frost & Sullivan validates our pursuit of a truly integrated platform that harmonizes AI-driven drug discovery with structure-based methodologies. It propels us toward achieving breakthroughs that once seemed unattainable and emphasizes our dedication to leading an innovative scientific frontier."

As the drug discovery ecosystem continues to evolve, Viva Biotech’s innovative approach, marked by the integration of advanced AI methodologies with experimental validation, places it at the forefront of the industry. Clients can expect even quicker advancements in preclinical programs, ultimately leading to the faster introduction of innovative therapies into the market.

For further insights into Frost & Sullivan's complete recognition and analysis of Viva Biotech, follow this link.

About Viva Biotech

Founded in 2008, Viva Biotech (01873.HK) offers comprehensive services, ranging from early-stage structure-based drug R&D to commercial manufacturing, catering to global biopharmaceutical innovators. The company employs a team of experts and state-of-the-art technology platforms to deliver tailored services across various therapeutic strategies and drug modalities, including small molecules and biologics. With robust capabilities in medicinal chemistry, custom synthesis, and comprehensive drug design support, Viva Biotech remains committed to addressing unmet medical needs and improving international healthcare outcomes.